BackAxonics Overview

Axonics Current Cash

Track Axonics's current cash ($240M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$239.45M
↑ 62.54% YoYΔ $92.13M vs prior year quarter

Peer trimmed avg / median

Loading

Axonics Current Cash History

Loading

Axonics vs. peers: Current Cash Comparison

Loading

Axonics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Axonics (AXNX) FAQ

As of the most recent data (September 2024), AXNX shows a current cash of $240M. That compares with $150M in the prior-year period — up 62.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AXNX's current cash is now $240M (was $150M) — a 62.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Axonics is outperforming or lagging.

Tracking AXNX's current cash over time shows whether Axonics is scaling, shrinking, or reshaping that part of the business. The current reading is $240M That compares with $150M in the prior-year period — up 62.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Axonics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $240M) with ownership activity and broader fundamentals.

Axonics's current cash is $240M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.